Related by context. All words. (Click for frequent words.) 70 antibody titer 69 lymphocyte count 69 PSA nadir 68 serum aminotransferase levels 68 serum urate levels 68 relapsed MM 67 glycated hemoglobin levels 67 serum HBV DNA 67 detectable HCV RNA 67 antiretroviral naïve 67 lactate dehydrogenase LDH 66 genotypic resistance 66 serum phosphorous 66 serum potassium 66 virological response 66 HbA1C 66 neutrophil counts 66 Pharmacokinetic parameters 66 Hb A1C 66 aspartate aminotransferase AST 66 HER2 expression 66 HBV DNA levels 66 glycosylated hemoglobin HbA1c 66 hematologic parameters 66 specific antigen PSA 66 Crohn Disease Activity 65 HBeAg seroconversion 65 tipranavir r 65 complete cytogenetic response 65 calculated creatinine clearance 65 PASI scores 65 prospectively stratified 65 serum urate 65 serum phosphate 65 HBsAg 65 intravascular hemolysis 65 virologic suppression 65 alanine aminotransferase 65 albumin excretion 64 elevated ALT 64 HbA1C levels 64 hematological parameters 64 HbA 1c levels 64 serum lipid levels 64 urine albumin 64 seroprotection 64 hepatitis C genotype 64 plasma renin activity 64 alanine aminotransferase ALT 64 HOMA IR 64 glycated hemoglobin HbA1c 64 HBeAg 64 Index CDAI 64 HIV RNA 64 hemoglobin A1c HbA1c 64 Hypotension 64 OGTT 64 HIV HCV coinfected 64 seropositivity 64 #.#ng/ml 64 HBV DNA 64 tipranavir ritonavir 63 hsCRP levels 63 creatinine ratio 63 glomerular filtration 63 Prostate specific antigen 63 sustained virological response 63 Tumor shrinkage 63 nonnucleoside reverse transcriptase inhibitors 63 HCV antibody 63 HIV coinfected 63 SCr 63 baseline HbA1c 63 microalbumin 63 hemoglobin concentrations 63 Non inferiority 63 PSADT 63 arterial oxygen saturation 63 aspartate aminotransferase 63 CIN3 63 -#.# log# 63 serum PSA 63 serum CRP 63 glycosylated hemoglobin levels 63 liver histology 63 certolizumab 63 undetectable viral 63 iPTH 63 Febrile neutropenia 63 ALT elevation 63 DAS# CRP 63 CR nPR 63 AST ALT 63 aminotransferase ALT 63 anagrelide 63 intact parathyroid hormone 63 hematopoietic cancers 63 acromegalic patients 63 plasma leptin 63 anti HBs 63 albumin excretion rate 63 Kinoid 63 virologic response 62 troponin T 62 Creatinine 62 virologic failure 62 biochemical relapse 62 transaminase elevations 62 plasma HCV RNA 62 #OHD levels 62 posttransplant 62 pretreatment serum 62 lactate dehydrogenase 62 sensitivity specificity 62 QTcF 62 Serum creatinine 62 thyroglobulin 62 serum cortisol 62 SUVmax 62 progression TTP 62 triglyceride concentrations 62 Postoperatively 62 Skin sterol 62 LV dysfunction 62 HER2 overexpression 62 undetectable HBV DNA 62 thrombocytopenic 62 baseline LDH 62 pegylated IFN 62 #mg dose [002] 62 IgG antibody 62 ADCS ADL 62 urate levels 62 Chlamydia trachomatis infection 62 microvessel density 62 BARACLUDE ® 62 serum ferritin 62 Myelosuppression 62 containing abacavir 62 serum phosphate levels 62 CDAI score 62 serum albumin 62 sUA 62 Secondary endpoints include 62 mg/m2 cohort 62 glomerular filtration rate 62 urinary albumin 62 spirometric 62 CD4 lymphocyte count 62 neutrophil count 62 epoetin alpha 62 tuberculin skin tests 62 CYP#D# genotype 62 serum concentrations 62 antiretroviral naive 62 moderate renal impairment 62 STELARA ® 62 fructosamine 62 colorectal adenoma 62 gemcitabine carboplatin 62 conditional logistic regression 62 Breslow thickness 61 antigen PSA levels 61 ADCS CGIC 61 recurrent venous thromboembolism 61 platelet reactivity 61 pT3 61 plasma pharmacokinetics 61 suboptimal adherence 61 MCyR 61 adenoma recurrence 61 elevated IOP 61 naïve HCV 61 abnormal cytology 61 tumor histology 61 coagulation abnormalities 61 Cystatin C 61 Homocysteine levels 61 IOP lowering 61 atherogenic dyslipidemia 61 UPDRS scores 61 elevated LDH 61 serum creatinine levels 61 hemoglobin Hb 61 SGPT 61 SCIg 61 EpCAM expression 61 azilsartan medoxomil 61 posttreatment 61 abacavir lamivudine 61 creatinine levels 61 parasitemia 61 pCR 61 histologic subtype 61 nonfasting triglyceride levels 61 neutropenic sepsis 61 serum antibody 61 endometrial thickness 61 mmHg diastolic 61 virologic 61 cTnT levels 61 transaminase levels 61 postoperative mortality 61 plasma folate 61 plasma viremia 61 recurrent genital herpes 61 #/#mmHg 61 serum calcium 61 undetectable HCV RNA 61 cardiac repolarization 61 confirmed CCyR 61 diabetic kidney 61 allogeneic HSCT 61 APTIVUS r 61 Capacity FVC 61 mean ± SEM 61 hemoglobin hematocrit 61 initiating antiretroviral therapy 61 virologic breakthrough 61 hemoglobin A1c levels 61 NIH CPSI 61 morphometric vertebral fractures 61 dalteparin 61 glycated hemoglobin 61 symptomatic intracranial hemorrhage 61 eosinophil count 61 carotid IMT 61 activated partial thromboplastin 61 leukocyte count 61 ALT normalization 61 hemagglutination inhibition HAI 61 potent antiretroviral therapy 61 node metastases 61 experienced virologic failure 61 NNRTI resistant virus 61 perioperatively 61 haematologic 61 CCyR 61 mIU ml 61 viraemia 61 ASCUS 61 genotype 1b 61 CD4 + cell 61 paricalcitol 61 Partial Response 61 transrectal ultrasound guided 61 aminotransferases 61 -#.# log# copies mL 61 STRIDE PD 61 undergo prostate biopsy 61 lymphocyte counts 61 estimated GFR 61 serum magnesium 61 TURBT 61 postintervention 60 viral titers 60 corrected QT interval 60 NNRTI resistance 60 corticosteroid dose 60 mg/m2 dose 60 plasma cortisol 60 angiographically 60 Lipitor #mg 60 BEXXAR Therapeutic Regimen 60 β blocker 60 HSCT 60 N telopeptide 60 cART 60 IU ml 60 co receptor tropism 60 reactogenicity 60 anti JCV antibodies 60 mild renal insufficiency 60 combination antiretroviral therapy 60 histological subtype 60 BCG vaccinated 60 dose escalation phase 60 viral load 60 Ceplene/IL-2 60 sUA levels 60 serum calcium levels 60 CPAP adherence 60 eNO 60 Diamyd r 60 adjuvant cisplatin 60 euthyroid 60 Cardiorespiratory fitness 60 im peramivir 60 annualized relapse 60 postexposure prophylaxis 60 mutated K ras 60 coinfected patients 60 antiangiogenic therapy 60 TMC# r 60 intracranial hemorrhage ICH 60 BENICAR HCT 60 % CI #.#-#.# [008] 60 Natalizumab 60 locoregional disease 60 digoxin toxicity 60 attain statistical significance 60 hA# 60 Hb A1c 60 ispinesib administered 60 Hemoglobin A1c 60 homocysteine concentrations 60 8mg/kg 60 Ribavirin causes 60 imatinib therapy 60 ritonavir boosted 60 triacylglycerol concentrations 60 KRAS mutation 60 serum HCV RNA 60 ACR# responses 60 Prostate Specific Antigen PSA 60 prospectively defined 60 MADRS score 60 serum testosterone 60 EDSS scores 60 HI titers 60 cTnI 60 echocardiographic parameters 60 System IPSS 60 anemia neutropenia 60 atazanavir ritonavir 60 deep venous thromboses 60 neutropaenia 60 pretransplant 60 HBV infections 60 Primary endpoints 60 achieved ACR# 60 mitoxantrone plus 60 repeat paracentesis 60 Proteinuria 60 Tasigna prolongs 60 Visual acuity 60 bronchial hyperresponsiveness 60 #ng/ml 60 viral kinetics 60 #dhTxB# 60 serum IgG 60 EGFR mutation positive 60 IFN alfa 60 resected pancreatic cancer 60 Naive Patients 60 latent tuberculosis TB 60 obstructive coronary artery 60 β blockers 60 Hepatotoxicity 60 serum markers 60 Sensitivity specificity 60 K ras mutations 60 Oncotype 60 elevated LDL cholesterol 60 serum homocysteine 60 macroalbuminuria 60 fosamprenavir 60 mcg BID 60 baseline A1C 60 ribavirin therapy 60 tropism testing 60 prolonged QT interval 60 serum clusterin levels 60 adenoma detection 60 methylmalonic acid 60 trastuzumab Herceptin ® 60 response CCyR 60 A1c levels 60 HAQ DI 60 chlamydial infection 60 SGOT 60 atypical ductal hyperplasia 60 CIMZIA ™ 60 clinically evaluable 60 Intravenous immunoglobulin 60 inflammatory biomarkers 60 HBeAg negative patients 60 undetectable hepatitis C 60 q8h 60 MMSE score 60 preoperative PSA 60 NMIBC 60 preintervention 60 log# copies mL 60 erythrocyte sedimentation rate 60 NSTE ACS 60 poor metabolizers 60 serum IgE 59 Retreatment 59 ADAS Cog 59 multivariable adjusted 59 Ishak fibrosis score 59 pharmacokinetic characteristics 59 interferon ribavirin 59 % Confidence Interval 59 PCA3 scores 59 Heavy menstrual bleeding 59 p# antigen 59 serum PTH 59 exhaled nitric oxide 59 elevated transaminases 59 hemoglobin A1C 59 CCR5 receptor antagonist 59 % CI #.#-#.# [003] 59 serum folate concentrations 59 seroconverted 59 ELISpot 59 transferrin saturation 59 hydroxy vitamin D 59 lupus anticoagulant 59 serum biomarkers 59 peak plasma concentrations 59 Kaplan Meier estimates 59 timepoints 59 ER CHOP 59 serum lactate 59 CrCl 59 definite stent thrombosis 59 PASI score 59 Renal Cell Carcinoma RCC 59 liver enzymes ALT 59 TMP SMX 59 CMV infection 59 XR NTX 59 Rectal cancer 59 paraprotein 59 ARB telmisartan 59 Gag polymorphisms 59 receiving VELCADE 59 KRAS status 59 lumbar spine BMD 59 Intraocular pressure 59 oral FTY# 59 steroid dexamethasone 59 PegIFN RBV 59 folate concentrations 59 intramuscular dose 59 achieved CCyR 59 squamous cell lung cancer 59 affective psychosis 59 pharmacodynamic parameters 59 radioiodine therapy 59 leukocyte counts 59 fasting plasma glucose FPG 59 HCV viral 59 Celsentri Selzentry 59 lymphocytosis 59 SpO 2 59 hepatorenal syndrome 59 ratio ICER 59 coagulation parameters 59 clinically asymptomatic 59 serum bicarbonate 59 bacteremic 59 methotrexate monotherapy 59 pegylated interferon alfa 59 cerebral oxygen saturation 59 virologically 59 bacteriuria 59 serum prostate 59 antidiabetic medication 59 tamoxifen Nolvadex ® 59 aminotransferase levels 59 tryptase 59 completely resected 59 CD# upregulation 59 NHANES III 59 hemodilution 59 ALT flares 59 buprenorphine implants 59 HBeAg + 59 serum ALT 59 cytomegalovirus infection 59 serum parathyroid hormone 59 symptom exacerbation 59 CANCIDAS 59 hemodynamic variables 59 lopinavir ritonavir plus 59 LDH lactate dehydrogenase 59 cEVR 59 pegylated alpha interferon 59 Secondary endpoints included 59 advanced neoplasia 59 DLQI 59 estimated glomerular filtration 59 8 OHdG 59 NNT = 59 protease inhibitor PI 59 moderately emetogenic 59 FluCAM arm 59 palivizumab 59 MS relapses 59 PRADAXA #mg 59 null responder HCV 59 metabolite concentrations 59 statistical significance p 59 canakinumab 59 sustained virologic response 59 mL/min/#.# m 2 59 HBeAg negative 59 confidence intervals CIs 59 hepatic fibrosis 59 NAbs 59 NIHSS 59 CC genotype 59 intradermal injections 59 HCV replicon 59 OnDose 59 microbiologically evaluable 59 Platelet counts 59 intraocular pressure IOP 59 CIN2 + 59 HIV seroconversion 59 receiving antiretroviral therapy 59 SVR# 59 HBeAg positive patients 59 maximal doses 59 recurrent glioblastoma multiforme 59 tolterodine ER 59 cerebral oxygenation 59 bronchoalveolar lavage 59 null responder 59 antiviral efficacy 59 galiximab 59 p = #.# [003] 59 pulmonary capillary wedge 59 bronchoalveolar lavage fluid 59 Amplicor 59 Insulin sensitivity 59 baseline CD4 59 CSF biomarkers 59 nonadherent 59 thyroid carcinoma 59 serologically 59 Brief Psychiatric 59 blood glucose concentrations 59 interferon beta therapy 59 hemagglutination inhibition 59 CK MB 59 oral prednisolone 59 nadir CD4 cell 59 invasive aspergillosis 59 Calcium intake 59 multivariate adjustment 59 dose Iluvien 59 overt nephropathy 59 Pegasys plus Copegus 59 viral tropism 59 postprocedure 59 fructose intolerance 59 #mg/day [001] 59 human chorionic gonadotropin hCG 59 urine NGAL 59 thyroid stimulating hormone 59 virological suppression 59 CCR5 tropic HIV 59 R0 resection 59 log# reduction 59 Platinol ® cisplatin 59 overt hypothyroidism 59 Glomerular Filtration Rate 59 Daptomycin 59 Fasting glucose 59 D dimer 59 oxycodone CR 59 multivariable analysis 59 Main Outcome Measure 59 serum sodium levels 59 darunavir r 59 median CD4 59 Index CDAI score 59 tuberculin skin testing 59 AZT zidovudine Retrovir 59 refractory SCLC 59 3mg/kg 59 salivary cortisol 59 clinico pathological 59 recurrent UTI 59 elevated creatinine 59 dose proportionality 59 LEXIVA r 59 aPTT 59 biochemical recurrence 59 imipenem 59 antiphospholipid antibodies 59 clinically meaningful reductions 59 univariate analyzes 59 DermaVir Patch 59 reduce serum phosphate 59 eculizumab therapy 59 cranial irradiation 59 Subgroup analyzes 59 hormone receptor status 59 microalbumin test 58 ritonavir boosted protease inhibitor 58 prostate specific 58 transfusion transmitted 58 HIV uninfected 58 octreotide LAR 58 GAMMAGARD 58 benazepril 58 REMINYL ® 58 beta carotene supplementation 58 desvenlafaxine succinate 58 μg L 58 virologic response EVR 58 naive HCV 58 SELENA SLEDAI 58 pulmonary exacerbations 58 nevirapine regimen 58 hours postdose 58 antibiotic susceptibility 58 Genetic mutation 58 ß blockers 58 Symptom severity 58 pmol L 58 pg ml 58 NPH insulin 58 hormone receptor negative 58 Randomized trials 58 IU mL 58 elevated triglyceride levels 58 pharmacodynamic PD 58 symptomatic intracranial 58 granulocyte 58 ALT AST 58 fluvastatin 58 tipranavir 58 colorectal neoplasms 58 virologic responses 58 adiponectin concentrations 58 CYT# potent vascular disrupting 58 Gastrointestinal Stromal Tumors 58 baseline FEV 58 Cotinine 58 BCR ABL mutations 58 serum estradiol 58 adult chronic ITP 58 serum lipid 58 coinfection 58 Sustained virologic response 58 baseline Hb 58 foveal thickness 58 EDSS score 58 IR Cysteamine 58 ADAS cog 58 sero positive 58 nucleotide analog 58 Hematocrit 58 doxorubicin docetaxel 58 atorvastatin #mg 58 concomitant antibiotics 58 Cardiotoxicity 58 INFERGEN 58 postoperative chemotherapy 58 Pemetrexed 58 serum glucose 58 circulating endothelial cells 58 advanced adenoma 58 myocardial necrosis 58 latent tuberculosis infection 58 cystoscopic 58 K#N 58 cardiac troponin T 58 glulisine 58 transfusion syndrome 58 plasma triglycerides 58 rheumatoid factor 58 serum IGF 58 receiving VICTRELIS 58 undetectable virus HCV 58 parasitological 58 Hp2 2 58 del 5q MDS 58 glycosylated hemoglobin 58 de novo AML 58 Secondary efficacy endpoints 58 cardiovascular calcification 58 dose atorvastatin 58 Bone density 58 REYATAZ r arm 58 cytologic 58 Suboptimal 58 Pegylated Interferon 58 Clinically significant 58 K DOQI 58 symptom flare ups 58 P. falciparum malaria 58 SLNB 58 clodronate 58 #Gy 58 multivariable logistic regression 58 PCNSL 58 humoral responses 58 uninfected infants 58 seroprotective 58 QTc prolongation 58 clinicopathological features 58 intravitreal injections 58 sitosterol 58 dosing frequency 58 hematologic toxicity 58 locoregional recurrence 58 SSc 58 postoperative complication 58 clinically meaningful improvement 58 thrombocytosis 58 HIV tropism 58 #mg q8h 58 radiotherapy RT 58 virus HBV 58 leukocytosis 58 elevated bilirubin 58 histologically confirmed 58 EDARBI 58 BMI z 58 plus methotrexate 58 antibody titers 58 parasitaemia 58 liver transplant recipients 58 pleural fluid 58 HpSA 58 seroconversion 58 QT QTc interval 58 carcinoembryonic antigen 58 treatment naive genotype 58 IV bisphosphonates 58 intracerebral haemorrhage 58 bacillus Calmette Guerin 58 intensive statin therapy 58 amisulpride 58 antiandrogen 58 venlafaxine XR 58 trough FEV1 58 p# activation 58 TPV r 58 anemia hemoglobin 58 lamivudine refractory patients 58 liver metastasis 58 metastatic neuroendocrine tumors 58 CFQ R 58 hepatic enzymes 58 adverse cytogenetics 58 urinary albumin excretion 58 alemtuzumab treated 58 Forodesine HCl 58 Fasting plasma glucose 58 pharmacokinetic PK profile 58 immune reconstitution syndrome 58 CP CPPS 58 pegIFN 58 HepC 58 receiving APTIVUS r 58 vincristine doxorubicin 58 antigen PSA 58 serologic testing 58 neonatal morbidity 58 genital secretions 58 pentoxifylline 58 procalcitonin 58 abnormal lipid 58 #mg/m# [002] 58 dose cohort 58 prednisone prednisolone 58 CK # plasma concentrations 58 undetectable viral load 58 p# biomarker 58 VKORC1 58 RSV hospitalizations 58 indinavir 58 NIASPAN 58 μmol L 58 transdermal estradiol 58 Immune reconstitution syndrome 58 serologically active patients 58 severe neutropenia 58 autoantibody levels 58 Follicular Lymphoma 58 symptomatic VTE 58 atheroma volume 58 #mg ATC 58 clomipramine 58 d dimer 58 Combination antiretroviral therapy 58 immunosuppression therapy 58 Kaplan Meier estimate 58 c reactive protein 58 Cystic Fibrosis Questionnaire Revised 58 fasting triglyceride levels 58 OnDose TM 58 BRAF V#E mutation 58 Negative Symptoms 58 EGFR mutation status 58 venous thromboembolic disease 58 Troponin T 58 Kaplan Meier analysis 58 Tumor Response 58 liver transaminases 58 serum uric acid 58 Arterial stiffness 58 Triglyceride levels 58 bepotastine besilate nasal spray 58 visceral metastases 58 antitumor effect 58 bezafibrate 58 Glomerular filtration rate 58 perioperative morbidity 58 Circulating tumor cells 58 SHBG levels 58 Drug eluting stent 58 Virologic failure 58 serum phosphorus 58 FOLFOX6 58 Immune responses 58 hepatic function 58 univariate 58 polyp recurrence 58 Fasting blood glucose 58 operable breast cancer 58 FDA defined valvulopathy 58 APTIVUS R 58 periprocedural 58 Hematologic toxicity 58 Subgroup analysis 58 reticulocytes 58 decompensated liver disease 58 Femara letrozole 58 polytherapy 58 multivariate analyzes 58 mesalamine granules 58 Warfarin Coumadin 58 estramustine 58 postdischarge 58 relapsed ALL 58 TT genotype 58 bioavailable testosterone 58 treat NNT 58 timepoint 58 nodal metastasis 58 Cmax 58 hip BMD 58 Prostate Specific Antigen 58 beta blocker therapy 58 troponins 58 irbesartan 58 Virologic 58 Nilotinib 58 mCRPC 58 DLTs 58 TDF FTC 58 CYP#D# inhibitor 58 slow progressors 58 rFSH 58 subclinical disease 58 cTnT 58 -#.# mg dL [001] 58 transgene expression 58 recurrent VTE 58 Gram stain 58 nicardipine 58 discontinued Viread 58 labetalol 58 sweat chloride 58 Insulin PH# 58 6MWD 58 postoperative pulmonary 58 colorectal neoplasia 58 dosing cohort 58 Hormone receptor 58 lipid elevations 58 CYP#A# substrate 58 serum creatinine 58 myocardial reperfusion 58 virologically suppressed 57 Genotypic 57 #OHD 57 nitroprusside 57 chronic hepatitis cirrhosis 57 mRS 57 urolithiasis 57 serum thyroglobulin 57 plasma creatinine 57 basal cell nevus syndrome 57 achieving PASI 57 PREZISTA r arm 57 ibandronate 57 isoenzyme 57 Opportunistic infections 57 zoledronic acid Reclast 57 fetal malformations 57 postprandial glycemia 57 Known hypersensitivity 57 sacral neuromodulation 57 multivariate Cox 57 acute GvHD 57 NQO1 57 radiographic outcomes 57 gonococcal infection 57 arterial thromboembolic events 57 Ejection Fraction 57 fasting triglycerides 57 smoldering myeloma 57 specific IgE 57 plus prednisone prednisolone 57 abacavir Ziagen 57 FUSILEV enhances 57 NMP# protein 57 KRAS mutant tumors 57 Amgen Neulasta R 57 creatinine clearance 57 inhibin B 57 busulfan 57 coronary calcification 57 antithymocyte globulin 57 enteroviral 57 mmHg systolic 57 hyperphenylalaninemia HPA due 57 FeNO 57 clinically insignificant 57 serum LDL cholesterol 57 S. aureus isolates 57 thyrotropin levels 57 undetectable PSA 57 de novo kidney transplant 57 warfarin dosage 57 left ventricular diastolic 57 multivariable analyzes 57 Patients Receiving 57 Telintra 57 inhaled iloprost 57 creatine kinase 57 Xelox 57 hypofractionated radiation 57 low expressors 57 serum potassium levels 57 CTAP# Capsules 57 Severity MSCS score 57 prednisone prednisolone plus 57 Fibromyalgia Impact Questionnaire 57 DAS# remission 57 prostate carcinoma 57 smoldering multiple myeloma 57 renal biopsy 57 dysmenorrhoea 57 pyrazinamide 57 Liver biopsy 57 exhaled NO 57 Albuminuria 57 underwent surgical resection 57 p = NS 57 extracapsular extension 57 noninferior 57 abnormal clotting 57 P aeruginosa 57 oral antidiabetes 57 Prognostic factors 57 preterm neonates 57 Univariate analysis 57 immunostaining 57 induced sputum 57 LAB CGRP 57 peginterferon alfa 57 Infusion Reactions Severe 57 hemoglobin concentration 57 Oral corticosteroids 57 myocardial infarctions MIs 57 hemostatic efficacy 57 MAGE A3 ASCI 57 GH deficiency 57 latent celiac disease 57 prostate cancer CaP 57 rimonabant #mg 57 aldosterone antagonist 57 protease inhibitor mutations 57 PLX STROKE targeting 57 BRCA2 mutation carriers 57 neurologic progression 57 quasispecies 57 receiving XGEVA 57 decompensated cirrhosis 57 blood Phe levels 57 DAS# scores 57 nevirapine Viramune 57 Helicobacter pylori eradication 57 liver biopsies 57 hypercalciuria 57 nonvertebral fracture 57 bronchopulmonary dysplasia BPD 57 EGFR TKI 57 perioperative mortality 57 postoperative AF 57 Endothelial function 57 hemoglobin A1C HbA1C 57 diastolic blood pressures 57 riboflavin vitamin B2 57 ascending dose 57 HCV RNA 57 Inhibin B 57 FDG-PET/CT